Market Access News | pharmaphorum

News

Boost to Enhertu's prospects as FDA clears Roche diagnostic

Roche gets the first FDA approval for a diagnostic test for HER2-ultralow breast cancer, now on the label of AstraZeneca and Daiichi Sankyo's Enhertu.

News

CHMP backs Bavarian Nordic's chikungunya jab

Bavarian Nordic is likely just weeks away from bringing the second chikungunya vaccine to the EU, and the first approved for use in adolescents.

News

AstraZeneca abandons plan for £450m vaccine plant in UK

In a shock move, AstraZeneca has ditched its plan to invest £450m in a new vaccine manufacturing plant in the UK.

News

EMA experts will look again at Leqembi's safety data

It seems Eisai and Biogen have another hurdle to jump over in their bid to get EU approval for their Alzheimer's disease therapy Leqembi.

News

Sickle cell gene therapy Casgevy finally cleared for NHS use

Vertex's gene-editing therapy for sickle cell disease, Casgevy, has been given the nod for use by the NHS in England after an earlier rejection.

News

Vertex bags FDA okay for its non-opioid pain drug

Vertex gets FDA approval for its non-opioid pain drug suzetrigine, the first new class of pain medicine in the US in more than 20 years.

Boost to Enhertu's prospects as FDA clears Roche diagnostic

CHMP backs Bavarian Nordic's chikungunya jab

AstraZeneca abandons plan for £450m vaccine plant in UK

EMA experts will look again at Leqembi's safety data

Sickle cell gene therapy Casgevy finally cleared for NHS use

Vertex bags FDA okay for its non-opioid pain drug

Amazon puts $100m into global health drive

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks